search
Back to results

RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients

Primary Purpose

Peripheral Arterial Disease, Sedentary Behavior, Sedentary Time

Status
Not yet recruiting
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
RESPONSE-2-PAD
Sponsored by
National Institute for Prevention and Cardiovascular Health, Ireland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Peripheral Arterial Disease focused on measuring peripheral arterial disease, sedentary lifestyle, Sitting time

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults (≥18 years), Symptomatic patients with established peripheral arterial disease. PAD is confirmed by any of the following: Ankle-brachial index (ABI) of less than 0.90 in at least one lower extremity Toe brachial index of less than 0.60 Arterial occlusive disease in one lower extremity by duplex ultrasonography, computed tomographic angiography or magnetic resonance angiography. Willing and able to give informed consent. Can read and speak English. Exclusion Criteria: patients with significant PAD in the form of rest pain. Any impairments that severely affect mobility (e.g., wheelchair bound). Cognitive impairments revealed by medical records. Significant comorbid disease that would significantly impair the ability to participate in activity. Pregnant / lactating females.

Sites / Locations

  • National Institute for prevention and Cardiovascular Health

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RESPONSE-2-PAD

Arm Description

All participants will use the activPAL accelerometer to quantify sedentary time/physical activity. The 6-minute-walk test will be assessed. Participants will receive the 12 week tailored intervention (RESPONSE-2-PAD link, coaching calls and activity tracker). Participants will be followed up at 12-weeks and again at six months.

Outcomes

Primary Outcome Measures

Evaluating the impact of the Multicomponent Intervention (RESPONSE-2-PAD) on sedentary time in individuals with PAD.
This study will assess sedentary time in hours at baseline. After a 12-week intervention and a 6-month follow-up, sedentary time will be reassessed using the activPAL accelerometer, as done at baseline. Data analysis will evaluate changes in sedentary time from baseline to post-intervention using statistical methods to assess the effectiveness of the multicomponent intervention.
Assessing the participant involvement in RESPONSE-2-PAD Intervention to Reduce Sedentary Time.
This study aims to evaluate the level of participant engagement in the RESPONSE-2-PAD intervention, which is designed to reduce sedentary time. Through a semi structured interview. We will assess participants' involvement, motivation, and adherence to the intervention.

Secondary Outcome Measures

Assessing the change in physical activity level in individuals with PAD using a Multicomponent Intervention (RESPONSE-2-PAD).
Moderate to vigorous physical activity (MVPA) hours will be assessed at baseline. After the intervention period (12 weeks) and 6 months follow up will be reassessed using the activPAL accelerometer as before the intervention. Then data will be analyzed to assess the changes in MVPA from baseline to post-intervention. Statistical methods will be employed to compare pre- and post-intervention MVPA and evaluate the effectiveness of the multicomponent intervention.
Assessing the Efficacy of the RESPONSE-2-PAD Program Using the 6-Minute Walk Test (6MWT) to Improve Symptom-Free Walking Distance.
This study aims to evaluate the effectiveness of the RESPONSE-2-PAD program in improving symptom-free walking distance using the six-minute walking test (6MWT). The assessment will include measuring total meters scored, initial claudication distance, and absolute claudication distance in participants with peripheral arterial disease (PAD).

Full Information

First Posted
July 10, 2023
Last Updated
July 18, 2023
Sponsor
National Institute for Prevention and Cardiovascular Health, Ireland
search

1. Study Identification

Unique Protocol Identification Number
NCT05961943
Brief Title
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
Official Title
Feasibility, Acceptability, and Effectiveness of the "RESPONSE-2" Program in Reducing Sedentary Behavior in Patients With Peripheral Arterial Disease: A Mixed Methods Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute for Prevention and Cardiovascular Health, Ireland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The RESPONSE-2- peripheral arterial disease (PAD) program will be implemented to modify sedentary time in patients with PAD. It is an adapted version of the RESPONSE that aims to reduce sedentary behavior in individuals with diabetes. The RESPONSE-2-PAD is a multicomponent program involves an online educational component, sedentary reminders and health coaching sessions, which are designed to modify patients' sedentary behavior.
Detailed Description
Peripheral arterial disease (PAD) affects more than 200 million patients globally. PAD is characterized by a reduction in arterial perfusion caused by atherosclerotic plaque. PAD can negatively impact a person's quality of life due to the functional limitations caused by symptoms and the possibility of losing limbs. It also increases the risk of major adverse cardiac events (MACE). Many risk factors have been identified for PAD. Recently, sedentary behavior (SB) has emerged as an important risk factor for cardiovascular disease (CVD) including PAD independent to physical activity. Studies have reported that patients with PAD have significantly higher levels of total sedentary time (ST) compared to those without PAD. Consequently, early intervention and management strategies, including addressing sedentary behavior, are crucial to prevent unfavorable outcomes in patients with established PAD as it is possible for an individual to engage in a significant amount of moderate to vigorous physical activity and have high levels of sedentary time within the same day. The RESPONSE-2-PAD program will be evaluated in a pilot study involving 50 patients living with peripheral arterial disease. They will be recruited through the vascular services at University Hospital Galway. Those potentially interested will be provided with an information sheet. Participants will take part in an initial assessment which will measure their sitting time, physical activity participation and their six-minute walking distance. They will then take part in a 12-week individually tailored, coaching-based intervention. This intervention will be delivered remotely. The intervention involves the use of an activity tracker(sedentary reminder) and an online structured education program coupled with coaching calls (10-15minutes) that review sitting time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment where sitting time, activity participation and six-minute walking distance will be remeasured. Patients will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurement of their sitting time, physical activity participation and six-minute walking distance in order to evaluate longer term changes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Sedentary Behavior, Sedentary Time, Peripheral Arterial Occlusive Disease
Keywords
peripheral arterial disease, sedentary lifestyle, Sitting time

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Study recruitment will be conducted at the vascular outpatient clinic at Galway University Hospitals (GUH), Ireland. Those who consent will then be invited to attend a baseline assessment. All participants will be provided with an activPAL accelerometer device to use for seven consecutive days. Patients will also complete the six-minute walk test (6-MWT). Participants will then commence the 12-week tailored intervention to empower participants to reduce/interrupt their sedentary time. Participants will have access to an online education session via the RESPONSE-2-PAD link. The researcher will support and motivate participants to reduce/interrupt their sitting time by contacting them through phone or video coaching calls once a week, on average lasting 10-15 minutes. an activity tracker will be used as a sedentary reminder. Participants will be followed up at 12-weeks and again at six months.
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RESPONSE-2-PAD
Arm Type
Experimental
Arm Description
All participants will use the activPAL accelerometer to quantify sedentary time/physical activity. The 6-minute-walk test will be assessed. Participants will receive the 12 week tailored intervention (RESPONSE-2-PAD link, coaching calls and activity tracker). Participants will be followed up at 12-weeks and again at six months.
Intervention Type
Behavioral
Intervention Name(s)
RESPONSE-2-PAD
Intervention Description
The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.
Primary Outcome Measure Information:
Title
Evaluating the impact of the Multicomponent Intervention (RESPONSE-2-PAD) on sedentary time in individuals with PAD.
Description
This study will assess sedentary time in hours at baseline. After a 12-week intervention and a 6-month follow-up, sedentary time will be reassessed using the activPAL accelerometer, as done at baseline. Data analysis will evaluate changes in sedentary time from baseline to post-intervention using statistical methods to assess the effectiveness of the multicomponent intervention.
Time Frame
Participants recruited for 6 months. Sedentary time assessed at baseline, after 12-week intervention, and at 6-month follow-up. Comprehensive evaluation of sedentary behavior throughout the study.
Title
Assessing the participant involvement in RESPONSE-2-PAD Intervention to Reduce Sedentary Time.
Description
This study aims to evaluate the level of participant engagement in the RESPONSE-2-PAD intervention, which is designed to reduce sedentary time. Through a semi structured interview. We will assess participants' involvement, motivation, and adherence to the intervention.
Time Frame
At the end of the 6-month follow-up period, participants will be interviewed to gather qualitative feedback.
Secondary Outcome Measure Information:
Title
Assessing the change in physical activity level in individuals with PAD using a Multicomponent Intervention (RESPONSE-2-PAD).
Description
Moderate to vigorous physical activity (MVPA) hours will be assessed at baseline. After the intervention period (12 weeks) and 6 months follow up will be reassessed using the activPAL accelerometer as before the intervention. Then data will be analyzed to assess the changes in MVPA from baseline to post-intervention. Statistical methods will be employed to compare pre- and post-intervention MVPA and evaluate the effectiveness of the multicomponent intervention.
Time Frame
Participants recruited for 6 months. MVPA assessed at baseline, after 12-week intervention, and at 6-month follow-up.
Title
Assessing the Efficacy of the RESPONSE-2-PAD Program Using the 6-Minute Walk Test (6MWT) to Improve Symptom-Free Walking Distance.
Description
This study aims to evaluate the effectiveness of the RESPONSE-2-PAD program in improving symptom-free walking distance using the six-minute walking test (6MWT). The assessment will include measuring total meters scored, initial claudication distance, and absolute claudication distance in participants with peripheral arterial disease (PAD).
Time Frame
6-Minute Walk Test (6MWT) Assessments: Baseline: Before starting the intervention Post-Intervention: At the end of the 12-week intervention period Follow-Up: 6 months after the completion of the intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years), Symptomatic patients with established peripheral arterial disease. PAD is confirmed by any of the following: Ankle-brachial index (ABI) of less than 0.90 in at least one lower extremity Toe brachial index of less than 0.60 Arterial occlusive disease in one lower extremity by duplex ultrasonography, computed tomographic angiography or magnetic resonance angiography. Willing and able to give informed consent. Can read and speak English. Exclusion Criteria: patients with significant PAD in the form of rest pain. Any impairments that severely affect mobility (e.g., wheelchair bound). Cognitive impairments revealed by medical records. Significant comorbid disease that would significantly impair the ability to participate in activity. Pregnant / lactating females.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marwa Said
Phone
00353877374710
Email
m.said2@nuigalway.ie
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer Jones
Organizational Affiliation
University of Galway
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wael Tawfick
Organizational Affiliation
University of Galway
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Charlotte Edwardson
Organizational Affiliation
University of Leicester
Official's Role
Study Chair
Facility Information:
Facility Name
National Institute for prevention and Cardiovascular Health
City
Galway
ZIP/Postal Code
H91 FF68
Country
Ireland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Jones
Phone
0035391893299
Email
Jennifer.jones@universityofgalway.ie
First Name & Middle Initial & Last Name & Degree
Wael Tawfick
Phone
0035391542376
Email
wael.tawfick@hse.ie
First Name & Middle Initial & Last Name & Degree
Jennifer Jones
First Name & Middle Initial & Last Name & Degree
Wael Tawfick
First Name & Middle Initial & Last Name & Degree
Marwa Said

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Only the relevant data will be collected and stored in Galway university hospital. The data relevant to this study will only be stored for 5 more years after the thesis is written and the research has been published in peer-reviewed journals.
IPD Sharing Time Frame
Data will be available to the other researchers on request for 5 years
IPD Sharing Access Criteria
The data will be in an encrypted file and will be stored at a secure database in Galway University Hospital. Only the coded data information will be shared.
Citations:
PubMed Identifier
33741077
Citation
Bailey DP, Edwardson CL, Pappas Y, Dong F, Hewson DJ, Biddle SJH, Brierley ML, Chater AM. A randomised-controlled feasibility study of the REgulate your SItting Time (RESIT) intervention for reducing sitting time in individuals with type 2 diabetes: study protocol. Pilot Feasibility Stud. 2021 Mar 19;7(1):76. doi: 10.1186/s40814-021-00816-0.
Results Reference
background
PubMed Identifier
29482617
Citation
Chastin SFM, Dontje ML, Skelton DA, Cukic I, Shaw RJ, Gill JMR, Greig CA, Gale CR, Deary IJ, Der G, Dall PM; Seniors USP team. Systematic comparative validation of self-report measures of sedentary time against an objective measure of postural sitting (activPAL). Int J Behav Nutr Phys Act. 2018 Feb 26;15(1):21. doi: 10.1186/s12966-018-0652-x.
Results Reference
background
PubMed Identifier
25907181
Citation
Martin A, Fitzsimons C, Jepson R, Saunders DH, van der Ploeg HP, Teixeira PJ, Gray CM, Mutrie N; EuroFIT consortium. Interventions with potential to reduce sedentary time in adults: systematic review and meta-analysis. Br J Sports Med. 2015 Aug;49(16):1056-63. doi: 10.1136/bjsports-2014-094524. Epub 2015 Apr 23.
Results Reference
background

Learn more about this trial

RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients

We'll reach out to this number within 24 hrs